Diabetic nephropathy: Prescription trends in tertiary care

Indian Journal of Pharmaceutical Sciences

Volumn 70, Issue 3, 2008, Pages 374-378

  Devi, D ^a   George, Jennifer ^b  

^a ST JOHN'S NATIONAL ACADEMY OF HEALTH SCIENCES   (India)

^b KVG College of Engineering   (India)

Author keywords

Calcium channel blockers; Diabetic nephropathy; Hypertension; Prescribing trends

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFECTIVE AGENT; ANTIULCER AGENT; CALCIUM CARBONATE; CALCIUM CHANNEL BLOCKING AGENT; CARDIOVASCULAR AGENT; CEPHALOSPORIN DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FUROSEMIDE; GASTROINTESTINAL AGENT; GENERIC DRUG; HISTAMINE H2 RECEPTOR ANTAGONIST; INSULIN; METRONIDAZOLE; OMEPRAZOLE; ORAL ANTIDIABETIC AGENT; PANTOPRAZOLE; PRAZOSIN; PROTON PUMP INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RANITIDINE;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; DEMOGRAPHY; DIABETIC NEPHROPATHY; DRUG UTILIZATION; FEMALE; HOSPITAL PATIENT; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; POLYPHARMACY; PRESCRIPTION; PROSPECTIVE STUDY; TERTIARY HEALTH CARE; WORLD HEALTH ORGANIZATION;

EID: 52149110200     PISSN: 0250474X     EISSN: 19983743     Source Type: Journal    
DOI: 10.4103/0250-474X.43007     Document Type: Article

References (13)

1. Baba T, Neugebauer S, Watanabe T. Diabetic neophropathy: Its relationship to hypertension and means of pharmacological intervention. Drugs 1997;54:198-22.
2. Parving HH. Benefits of and cost of antihypertensive treatment in incipient and overt diabetic nephropathy. J Hypertens Suppl 1998;16(1) S99-101.
3. Ismail N, Becker B, Strezekzyk P, Ritz E. Renal disease and hypertension in non insulin dependent diabetes mellitus. Kidney Int 199;55:1-28.
4. Srishyla MV, Krishnamurthy M, Nagarani MA, Andrade C, Venketaraman BV. Prescription audit in an Indian hospital setting using the DD concept. Indian J Pharmacol 1994;26:23-8.
5. WHO collaborating Centre for Drug Statistics Methodology. Anatomic-therapeutic-chemical classification of drugs (ATC) Classification index. Oslo: Norway; 2005. Available from http://www.whocc.no/atcddd/.[cited 2005 Jan 15].
6. John L, Rao PS, Kangasabapathy AS. Prevalence of diabetic nephropathy in non-insulin dependent diabetes. Indian J Med Res 1991;94:24-9.
7. Freedman BI, Tuttle AB, Spray BJ. Familial predisposition to nephropathy in Africans and Americans with non-insulin dependent diabetes mellitus. Am J Kidney Dis 1995;25:710-3.
8. Viktil KK, Blix HS, Moger TA, Reikvam. Polypharmacy as commonly defined is an indicator of limited value in the assessment of drug related problems. Br J Clin Pharmacol 2007;63:187-95.
9. Bennet PN, Brown MJ. Clinical pharmacology. Edinburgh: Churchill Livingstone; 2003.
10. WHO model list of essential drugs; 13th ed. [revised on 2003 Apr]. Available from: http://www.who.int/medicines/organization/par/edl/expcom13/ EML13_en.doc. [cited on 2005 Mar 29].
11. Weir MR, Hanes DS, Klassen DK. Antihypertensive drugs. In: Brenner, Rector, editors. The Kidney. Vol 2. 7th ed. Philadelphia: Saunders Publishers; 2004. p. 2387-94.
12. Chobanian AV, Barkis GL, Black HR, Cushman WC, Green LA, Izzo J, et al. The seventh report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure. JAMA 2003;19:2560-9.
13. Marshall SM. Clinical features and management of diabetic nephropathy. In: Pickup, Willams G, editors. Text book of diabetes. Vol 2. Oxford: Blackwell; 2003. p. 76.6.